Pharmacyclics, Inc. (PCYC) Stock Ratings


View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:


Bearish

100% of 1 ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks
Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
Netteligent Netteligent 10/29/2014 1 month $130.85 $134.45 +2.75% -2 Active
Comments:
marcelo aniloel zampolli marcelo aniloel zampolli 08/24/2013 3 months $113.56 $126.09 +11.03% 11 Ended
Comments:
guydemangeon guydemangeon 08/24/2013 1 month $113.56 $119.21 +4.98% 4 Ended
Comments:
claudiodippolit claudiodippolit 08/13/2013 3 months $112.00 $121.46 +8.45% 8 Ended
Comments: The ibrutinib is an incredible discovery that will revolutionize medicine. Fair value 150 $
f.mariani04 f.mariani04 08/13/2013 3 months $110.29 $121.46 +10.13% 10 Ended
Comments: Read this... Fair value di 125 $ http://seekingalpha.com/article/1629942-expedited-drug-approval-ma
Yaroslav Yaroslav 08/10/2013 3 months $111.44 $114.23 +2.5% -2 Ended
Comments:
Alejandro Alejandro 01/23/2013 3 months $69.09 $81.69 +18.24% 18 Ended
Comments:
Doyee5 Doyee5 06/08/2012 3 months $39.49 $64.88 +64.29% 64 Ended
Comments: Industry sector growing or poised for growth
Juan Carlos_6 Juan Carlos_6 03/01/2012 3 months $26.64 $32.27 +21.13% 21 Ended
Comments: Industry sector growing or poised for growth
AlexFacey AlexFacey 07/12/2011 1 Year $11.89 $49.70 +318% 317 Ended
Comments: Industry sector growing or poised for growth

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.